Jonathan Mark Hopper - 24 Feb 2026 Form 4 Insider Report for Vericel Corp (VCEL)

Role
Chief Medical Officer
Signature
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Issuer symbol
VCEL
Transactions as of
24 Feb 2026
Net transactions value
-$75,177
Form type
4
Filing time
26 Feb 2026, 16:05:35 UTC
Previous filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hopper Jonathan Mark Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper 26 Feb 2026 0001626325

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCEL Common Stock Options Exercise +350 +0.49% 71,377 24 Feb 2026 Direct F1, F2, F3
transaction VCEL Common Stock Options Exercise $0 +3,150 +4.4% $0.000000 74,527 24 Feb 2026 Direct F3, F4
transaction VCEL Common Stock Tax liability $50,850 -1,335 -1.8% $38.09 73,192 24 Feb 2026 Direct F3, F5
transaction VCEL Common Stock Options Exercise +1,500 +2% 74,692 24 Feb 2026 Direct F1, F3, F6
transaction VCEL Common Stock Options Exercise $0 +1,500 +2% $0.000000 76,192 24 Feb 2026 Direct F3, F7
transaction VCEL Common Stock Tax liability $24,327 -636 -0.83% $38.25 75,556 24 Feb 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCEL Restricted Stock Unit Options Exercise +350 +2.6% 13,650 24 Feb 2026 Common Stock 350 Direct F2, F8, F9
transaction VCEL Restricted Stock Unit Options Exercise +3,150 +43% 10,500 24 Feb 2026 Common Stock 3,150 Direct F4, F8, F9, F10
transaction VCEL Restricted Stock Unit Options Exercise +1,500 +25% 7,500 24 Feb 2026 Common Stock 1,500 Direct F6, F8, F9
transaction VCEL Restricted Stock Unit Options Exercise +1,500 +33% 6,000 24 Feb 2026 Common Stock 1,500 Direct F7, F8, F9, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
F2 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
F3 These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F4 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.
F5 These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
F6 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
F7 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively.
F8 Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F9 No expiration date for this type of award.
F10 The Fair Market Value of the vested derivative securities is $38.09 per share.
F11 The Fair Market Value of the vested derivative securities is $38.25 per share.